Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.925 SEK | +1.09% | -9.14% | +34.25% |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 753.9 | 567.5 | 566.9 | 341.9 | 453.3 | 701.2 | - | - |
Enterprise Value (EV) 1 | 574 | 476.3 | 298.5 | 269.1 | 403.3 | 403.5 | 701.2 | 701.2 |
P/E ratio | -3.59 x | -3.96 x | -4.02 x | -1.76 x | -1.25 x | -1.74 x | -2.91 x | -7.71 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 140 x | 85.1 x | 37.5 x | 9.21 x | 7.32 x | 2.64 x | 5.17 x | 5.36 x |
EV / Revenue | 106 x | 71.4 x | 19.7 x | 7.25 x | 6.52 x | 1.52 x | 5.17 x | 5.36 x |
EV / EBITDA | -2.83 x | -3.59 x | -2.29 x | -1.49 x | -1.69 x | 58.2 x | -10.6 x | -13.5 x |
EV / FCF | -3.17 x | -3.37 x | -2.35 x | -1.56 x | -2.1 x | -2.01 x | -3.58 x | -10.6 x |
FCF Yield | -31.6% | -29.7% | -42.6% | -64.3% | -47.5% | -49.8% | -28% | -9.41% |
Price to Book | 2.92 x | 4.92 x | 2.01 x | 3.88 x | 34.5 x | 1.97 x | - | - |
Nbr of stocks (in thousands) | 71,389 | 71,389 | 220,585 | 220,585 | 657,954 | 758,039 | - | - |
Reference price 2 | 10.56 | 7.950 | 2.570 | 1.550 | 0.6890 | 0.9250 | 0.9250 | 0.9250 |
Announcement Date | 2/12/20 | 2/26/21 | 2/11/22 | 2/10/23 | 2/8/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 5.396 | 6.666 | 15.13 | 37.14 | 61.9 | 266.1 | 135.7 | 130.8 |
EBITDA 1 | -203 | -132.8 | -130.4 | -181 | -238.5 | 6.93 | -66.32 | -51.8 |
EBIT 1 | -214.5 | -144.3 | -141.6 | -192.8 | -249 | -1.32 | -72.82 | -58.3 |
Operating Margin | -3,975.17% | -2,164.69% | -936.14% | -519.16% | -402.22% | -0.5% | -53.68% | -44.57% |
Earnings before Tax (EBT) 1 | -210.1 | -143.3 | -141.7 | -193.4 | -248.6 | -0.98 | -72.32 | -57.8 |
Net income 1 | -210.1 | -143.3 | -141.7 | -193.4 | -248.6 | -0.98 | -72.32 | -57.8 |
Net margin | -3,893.85% | -2,149.65% | -936.8% | -520.81% | -401.58% | -0.37% | -53.31% | -44.19% |
EPS 2 | -2.940 | -2.010 | -0.6400 | -0.8800 | -0.5500 | -0.5330 | -0.3183 | -0.1200 |
Free Cash Flow 1 | -181.1 | -141.5 | -127.1 | -173 | -191.7 | -201 | -196 | -66 |
FCF margin | -3,357.08% | -2,122.02% | -840.13% | -465.99% | -309.76% | -75.53% | -144.46% | -50.46% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Announcement Date | 2/12/20 | 2/26/21 | 2/11/22 | 2/10/23 | 2/8/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | 180 | 91.3 | 268 | 72.8 | 50 | 298 | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | -181 | -141 | -127 | -173 | -192 | -201 | -196 | -66 |
ROE (net income / shareholders' equity) | -57.8% | -76.7% | -71.3% | -104% | -493% | -407% | -311% | -166% |
ROA (Net income/ Total Assets) | -51.3% | -61.9% | -58.4% | -76.9% | -173% | -156% | -119% | -50% |
Assets 1 | 409.6 | 231.5 | 242.5 | 251.4 | 144 | 0.6274 | 60.98 | 115.6 |
Book Value Per Share 2 | 3.620 | 1.610 | 1.280 | 0.4000 | 0.0200 | 0.4700 | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | 2.07 | 0.1 | 0.05 | 0.44 | 2.46 | 0.03 | - | - |
Capex / Sales | 38.34% | 1.53% | 0.3% | 1.18% | 3.97% | 0.01% | - | - |
Announcement Date | 2/12/20 | 2/26/21 | 2/11/22 | 2/10/23 | 2/8/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+34.25% | 63.95M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ATORX Stock
- Financials Alligator Bioscience AB